2 results about "Hydantoin derivatives" patented technology

This invention discloses a eutectic solvent and its preparation, a metal leaching agent, and a metal leaching method. The eutectic solvent is prepared by mixing choline chloride and a sulfonamide compound in a specific ratio; the sulfonamide compound is sulfonamide, 4-amino-N-(aminoiminomethyl)benzenesulfonic acid, or p-aminobenzenesulfonamide. This invention provides a metal leaching agent containing the aforementioned eutectic solvent, which is a transparent liquid prepared from the eutectic solvent and an auxiliary agent. The auxiliary agent is at least one selected from 1,3-dibromo-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, N-chlorosuccinimide, N-bromosuccinimide, chloramine T, and sodium hypochlorite. The eutectic solvent of this invention is an environmentally friendly compound, and the metal leaching agent system containing this eutectic solvent possesses both good oxidizing and coordinating abilities, enabling the leaching of gold and palladium with rapid leaching speed and high extraction rate.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.